← Back to Screener
Indaptus Therapeutics, Inc. Common Stock (INDP)
Price$1.92
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-15.36%
Price vs S&P 500 (4W)-22.73%
VGM Score38.05
Market Capitalization$199.31M
All Metrics
Book Value / Share (Quarterly)$0.01
P/TBV (Annual)0.70x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.15
Price vs S&P 500 (YTD)-50.45%
EPS (TTM)$-16.83
10-Day Avg Trading Volume0.13M
EPS Excl Extra (TTM)$-16.83
EPS (Annual)$-21.58
ROI (Annual)-661.54%
Cash / Share (Quarterly)$0.01
ROA (Last FY)-223.94%
EBITD / Share (TTM)$-4.86
ROE (5Y Avg)-249.93%
Cash Flow / Share (Annual)$-6.84
P/B Ratio159.72x
P/B Ratio (Quarterly)3.27x
Net Income / Employee (Annual)$-4,169,800
Net Interest Coverage (TTM)-17.08x
ROA (TTM)-299.68%
EPS Incl Extra (Annual)$-21.58
Current Ratio (Annual)1.51x
Quick Ratio (Quarterly)1.61x
3-Month Avg Trading Volume0.06M
52-Week Price Return-84.29%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.83
52-Week High$19.91
EPS Excl Extra (Annual)$-21.58
Tangible BV CAGR (5Y)-15.97%
26-Week Price Return0.57%
Quick Ratio (Annual)1.38x
13-Week Price Return-14.69%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.34x
Enterprise Value$197.81M
Book Value / Share Growth (5Y)-35.92%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$3.93
3-Month Return Std Dev135.87%
Net Income / Employee (TTM)$-3,771,500
ROE (Last FY)-661.54%
Net Interest Coverage (Annual)-6.11x
EPS Basic Excl Extra (Annual)$-21.58
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-16.83
Receivables Turnover (Annual)0.00x
ROI (TTM)-454.03%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.93
Price vs S&P 500 (52W)-112.49%
Year-to-Date Return-39.52%
5-Day Price Return44.26%
EPS Normalized (Annual)$-21.58
ROA (5Y Avg)-120.40%
Month-to-Date Return-37.14%
Cash Flow / Share (TTM)$-1.80
EBITD / Share (Annual)$-20.53
ROI (5Y Avg)-249.93%
EPS Basic Excl Extra (TTM)$-16.83
P/TBV (Quarterly)1.13x
P/B Ratio (Annual)1.62x
Book Value / Share (Annual)$1.45
Price vs S&P 500 (13W)-24.43%
Beta1.26x
Revenue / Share (TTM)$0.00
ROE (TTM)-454.03%
52-Week Low$0.92
mGradeD
vgmGradeD
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
INDPIndaptus Therapeutics, Inc. Common Stock | — | — | D | $1.92 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Indaptus Therapeutics is a pre-clinical biotechnology company developing a proprietary bacterial-based immunotherapy platform targeting cancer and viral infections. Its lead candidate, Decoy20, has demonstrated anti-tumor activity in preclinical models as both a single agent and in combination therapy across multiple cancer types, including colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma.